SPPI - Spectrum Pharmaceuticals, Inc.
| Previous Close | 8.10 |
| Open | 8.08 |
| Bid | 0.00 x 3000 |
| Ask | 0.00 x 1300 |
| Day's Range | 7.84 - 8.19 |
| 52 Week Range | 6.22 - 25.29 |
| Volume | 762,970 |
| Avg. Volume | 788,293 |
| Market Cap | 878.91M |
| Beta (3Y Monthly) | 3.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.17 |
| Earnings Date | Mar 7, 2017 - Mar 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2012-12-18 |
| 1y Target Est | 23.20 |
- Insider Monkey•24 days ago
Here’s What Hedge Funds Think About Spectrum Pharmaceuticals, Inc. (SPPI)
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
- Benzinga•29 days ago
The 5 Most Expensive Drugs In US: What You Should Know
The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers. Prices of drugs are staggeringly high in the U.S. when compared to other developed countries such as Japan and in Europe. House lawmakers are discussing a plan that could work to curb high drug prices.
- Business Wire•last month
Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors
Spectrum Pharmaceuticals, Inc. (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the appointment of Elizabeth Czerepak to the Board of Directors. Ms. Czerepak will also serve as the chair of Spectrum’s audit committee. “Elizabeth has a strong track record of financial leadership in various roles throughout her career including as a CFO, a venture capitalist and leader of business development groups,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.
- Simply Wall St.•last month
What Kind Of Investor Owns Most Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)?
A look at the shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) can tell us which group is most powerful...
- Zacks•last month
Ligand Inks Oncology Drug Discovery Deal With PhoreMost
Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.
- Zacks•last month
Why Is Spectrum Pharma (SPPI) Down 14.4% Since Last Earnings Report?
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•2 months ago
Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with a primary focus in hematology and oncology, today announced integrated analysis results from two Phase 3 clinical trials of ROLONTIS. ROLONTIS is a long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy. The analysis found that integrated efficacy and safety data from the two identically designed Phase 3 trials – ADVANCE and RECOVER – were consistent with results from the individual trials, demonstrating that ROLONTIS was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia (DSN) in all four cycles of treatment.
- Business Wire•2 months ago
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 Global Healthcare Conference on June 5th
Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.
- Business Wire•2 months ago
Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target
Spectrum Pharmaceuticals, Inc. (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the full enrollment of cohort 2 (N = 87) for previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations. Topline results from this cohort are expected by mid 2020. This is the second cohort that has met enrollment target in Spectrum’s ZENITH20 trial – an open-label, multi-center, global phase 2 trial evaluating NSCLC patients with EGFR or HER2 exon 20 insertion mutations.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of SPPI earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Spectrum Pharmaceuticals Inc Earnings Call
- Business Wire•2 months ago
Spectrum Pharmaceuticals to Present Corporate Update at the 20th Annual B. Riley FBR Investor Conference on May 23rd
Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the 20th Annual B. Riley FBR Investor Conference being held in Beverly Hills, CA. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.
Motley Fool•2 months agoSpectrum Pharmaceuticals, Inc. (SPPI) Q1 2019 Earnings Call Transcript
SPPI earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
- Associated Press•2 months ago
Spectrum Pharma: 1Q Earnings Snapshot
On a per-share basis, the Henderson, Nevada-based company said it had a loss of 17 cents. Losses, adjusted for one-time gains and costs, were 27 cents per share. Spectrum Pharma shares have climbed slightly ...
- Business Wire•2 months ago
Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update
HENDERSON, Nev.-- -- Topline results in the previously treated EGFR cohort of the poziotinib ZENITH20 trial are expected in Q4 2019. Integrated data from the two Phase 3 ROLONTIS ® clinical trials will be presented in a poster session at the American Society of Clinical Oncology 2019 annual meeting. Spectrum is working on filing the ROLONTIS Biologics License Application as soon as possible. Spectrum ...
- Business Wire•2 months ago
Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets
Spectrum Pharmaceuticals, Inc. (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the closure of an asset purchase and license agreement with ImmunGene, Inc., a privately held biotechnology company. The deal includes an exclusive license for the intellectual property related to the FIT antibody-interferon fusion technology drug delivery platform originally developed by scientists at UCLA. Research for this program received financial support through the Therapy Acceleration Program® of The Leukemia & Lymphoma Society, Inc. (LLS), and an LLS research grant to UCLA.
- Insider Monkey•2 months ago
Is Spectrum Pharmaceuticals, Inc. (SPPI) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and investors' positions as of the end of the fourth quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news websites. […]
- Business Wire•3 months ago
Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call
Spectrum Pharmaceuticals , announced today it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, May 9, 2019 at 4:30 p.m.
- Zacks•3 months ago
Analysts Estimate Spectrum Pharmaceuticals (SPPI) to Report a Decline in Earnings: What to Look Out for
Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•3 months ago
The Spectrum Pharmaceuticals (NASDAQ:SPPI) Share Price Has Gained 66% And Shareholders Are Hoping For More
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking i...
- Business Wire•4 months ago
Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 9
Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today that an overview of the company's business strategy and development-stage programs will be given at the H.C. Wainwright Global Life Sciences Conference being held in London. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology.
- Zacks•4 months ago
Why Is Spectrum Pharma (SPPI) Down 1.1% Since Last Earnings Report?
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•4 months ago
Report: Exploring Fundamental Drivers Behind ON Semiconductor, Pilgrim's Pride, Merck & Co., Healthcare Services Group, Genomic Health, and Spectrum Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•4 months ago
Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down
Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.
